In the dose-expansion phase of SCORES, which only included patients with recurrent or metastatic squamous cell carcinoma of the head and neck, ORRs were 5% among 22 previously untreated patients and 10% among the 20 patients who previously received a PD-L1 inhibitor [28, 29]. Here, CD274 is linked to metastatic squamous cell carcinoma.